Physicians' Academy for Cardiovascular Education

Treatment of patients on oral anticoagulation who present with ACS

Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA

No added value of monitoring platelet function after ACS

Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
##SCROLLER_ITEMS_FULL_TITLE##

No indication for difference in efficacy between potent platelet inhibitors after PCI

Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

C-Reactive Protein, Inflammation and Atherosclerosis

Jan. 24, 2016
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##SCROLLER_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

Sep. 29, 2015
##SCROLLER_ITEMS_FULL_TITLE##

The changing character of atherosclerotic disease

May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby

Cardiovascular Inflammation and Immunity in Atherosclerosis:

June 7, 2015 - Amsterdam
##SCROLLER_ITEMS_FULL_TITLE##

HDL mimetics: New promise in ACS?

Sep. 15, 2014 - Barcelona 2014 - Prof Kausik Ray MD
##SCROLLER_ITEMS_FULL_TITLE##

New registries on ACS/PCI: how does the real world look like

Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

Latest guidelines on ACS/PCI: what are the key changes?

Sep. 2, 2014 - Barcelona, ESC - Prof. Petr Widimsky, Prague, Czech Republic
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI :Patient cases based on real world data

Sep. 2, 2014 - Barcelona, ESC - Peter Sinnaeve, MD UZ Leuven
##SCROLLER_ITEMS_FULL_TITLE##

ACS/PCI: Patient cases based on latest guidelines

Sep. 1, 2014 - Barcelona, ESC - Professor Petr Widimský

Statin-loaded HDL nanoparticles

Jan. 23, 2014 - Raphaël Duivenvoorden - Raphaël Duivenvoorden

2017 ESC STEMI guidelines redefine important time points, with consequences for management choices

Jan. 16, 2018 - news

Two documents summarize the main messages of the ESC 2017 STEMI management guidelines, namely changes with respect to the 2012 version and ‘ten commandments’ to follow.

DAPT improves patency of saphenous vein graft at 1 year post-CABG

Presented at ACC.17 Scientific Sessions in Anaheim, CA, USA by Qiang Zhao (Ruijin Hospital, Shanghai)

Nov. 13, 2017 - news
The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

AHA 2017 The small DACAB study demonstrated that DAPT with ticagrelor plus aspirin more often showed patency of SVG and was associated with numerically lower MACE at 1 year as compared with aspirin alone.

Treatment of patients on oral anticoagulation who present with ACS

Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.

Using a case description and study data, dr. Jur ten Berg explains how management of these ACS patients differs from patients who are not anticoagulated with NOACs.

NOAC-based dual therapy is safer than triple therapy for stent placement in AF patients

ESC 2017 - Barcelona

Aug. 31, 2017 - news

ESC 2017 Fewer major bleedings with dual therapy of dabigatran and platelet inhibitor than with triple therapy with warfarin, platelet inhibitor and aspirin, in AF patients receiving a stent in RE-DUAL PCI..

Longer-term treatment with low-dose P2Y12 inhibitor lowers mortality in high-risk ACS patients

ESC 2017 - Barcelona

Sep. 3, 2017 - news

ESC 2017 PEGASUS substudy shows that continued treatment with ticagrelor within 2 years after MI or 1 year after stopping ADP receptor inhibition, reduces CV death in patients at high atherothrombotic risk.

GRAND DEBATE: Inflammation and cardiovascular disease

ESC 2017 - Barcelona

ESC 2017 Grand Debate
ESC 2017 Grand Debate

ESC 2017 One of the Grand Debates of course focused on different interpretations of the CANTOS trial data. Paul Ridker and Alberico Catapano debated how central inflammation is to CVD.

Causal relationship of central and general adiposity with CHD and T2DM

May 18, 2017 - Dale C, et al. - Circulation. 2017

Mendelian analysis confirms a causal relationship of both central and general adiposity with the risk of CHD and T2DM, whereas central adiposity was stronger linked to ischemic stroke.

Insights in association plasma apo CIII levels with CAD risk

May 9, 2017 - Van Capelleveen JC, et al. - ATVB 2017

Strong association between elevated plasma apo CIII levels with CAD risk may be due to elevated levels of remnant lipoproteins, small dense LDL and low-grade inflammation.

Very low LDL-C levels are safe and effective in high-risk post-ACS patients

Mar. 29, 2017 - Giugliano RP, et al. - JAMA Cardiol. 2017
Very low LDL-c as safe and effective as lower LDL-c levels in high-risk ACS patients of the IMPROVE-IT study

LDL-C levels <30 mg/dL at 1 month were associated with a similar safety profile and with numerical reductions in CV events compared with higher LDL-C levels in high-risk post-ACS patients.

Safety of NOAC instead of aspirin in ACS patients

Presented at ACC.17 by Magnus E Ohman

Mar. 18, 2017 - news

ACC 2017 A safety study of rivaroxaban versus aspirin on top of P2Y12 therapy in ACS patients, showed that this dual antithrombotic regimen had a similar risk of clinically significant bleeding.

Prognostic value of high sensitivity troponin I in diabetic post-ACS patients

Mar. 8, 2017 - Cavender MA, et al. - Circulation 2017

In diabetic post-ACS patients, the magnitude of high sensitivity troponin I elevation was an independent predictor of ischemic and heart failure events.

TZD reduces ACS risk in insulin-resistant non-diabetic patients with prior stroke or TIA

Mar. 8, 2017 - Young LH, et al. - Circulation 2017

Pioglitazone reduced the risk of acute coronary syndrome events, particularly type 2 MIs, in insulin resistant patients without diabetes but with a history of stroke or TIA.